HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

被引：0
|
作者：
Goulis, I. [1 ]
Akriviadis, E. [1 ]
Karatapanis, S. [2 ]
Deutsch, M. [3 ]
Dalekos, G. [4 ]
Raptopoulou-Gigi, M. [5 ]
Drakoulis, C. [6 ]
Bakalos, G. [7 ]
Papatheodoridis, G. [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Gen Hosp, Dept Internal Med 4, GR-54006 Thessaloniki, Greece
[2] Gen Hosp Rhodes, Dept Internal Med 1, Rhodes, Greece
[3] Univ Athens, Sch Med, Hippokrat Hosp, Dept Internal Med 2, GR-11527 Athens, Greece
[4] Univ Thessaly, Sch Med, Larisa, Greece
[5] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Hosp, Dept Internal Med 2, GR-54006 Thessaloniki, Greece
[6] Gen Hosp Nikaia, Dept Internal Med 2, Nikaia, Greece
[7] Roche Hellas, Athens, Greece
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60716-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
714
引用
收藏
页码：S286 / S287
页数：2
相关论文
共 50 条
  • [1] HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Mimidis, K.
    Germanidis, G.
    Triantos, C.
    Drakoulis, C.
    Chounta, A.
    Tsoplou, F.
    Zintzaras, E.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S201 - S202
  • [2] HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT
    Goulis, Loannis
    Akriviadis, Evangelos
    Karatapanis, Stylianos
    Deutsch, Melanie
    Dalekos, George N.
    Raptopoulou-Gigi, Maria P.
    Drakoulis, Christos
    Mimidis, Konstantinos
    Germanidis, Georgios
    Nikolopoulou, Vasiliki
    Chounta, Athina
    Bakalos, George
    Papatheodoridis, George V.
    HEPATOLOGY, 2011, 54 : 1019A - 1020A
  • [3] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [4] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
  • [5] The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B
    Kowalik, E.
    Niewada, M.
    Jakubczyk, M.
    Horban, A.
    Berak, H.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A300
  • [6] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [7] SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Lampertico, Pietro
    Vigano, Mauro
    Di Costanzo, Giovan Giuseppe
    Sagnelli, Evangelista
    Fasano, Massimo
    Di Marco, Vito
    Boninsegna, Sara
    Farci, Patrizia
    Fargion, Silvia
    Giuberti, Tiziana
    Iannacone, Claudio
    Massetto, Benedetta
    Martins, Eduardo B.
    Colombo, Massimo
    HEPATOLOGY, 2010, 52 (04) : 387A - 387A
  • [8] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-NEGATIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A277 - A277
  • [9] Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B
    Marcellin, P
    Bonino, F
    Lau, GY
    Farci, P
    Yurdaydin, C
    Piratvisuth, T
    Jin, R
    Gurel, S
    Hadziyannis, S
    Lu, ZM
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 580A - 580A
  • [10] Extended Peginterferon Alfa-2a (Pegasys) Therapy in Chinese Patients With HBeAg-Negative Chronic Hepatitis B
    Chen, Xuefu
    Chen, Xiaoping
    Chen, Wenli
    Ma, Xiaojun
    Huang, Jing
    Chen, Ren
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (10) : 1705 - 1713
12345